Viatris Inc VIA

XET: VIA | ISIN: US92556V1061   12/11/2024
12,19 EUR (-0,45%)
(-0,45%)   12/11/2024

11 september 2024 · Viatris Announces Expiration and Results of Any and All Cash Tender Offers · Persbericht

10 september 2024 · Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers · Persbericht

4 september 2024 · Viatris Announces Cash Tender Offers for Certain Outstanding Notes · Persbericht

23 augustus 2024 · Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress · Persbericht

8 augustus 2024 · Viatris Reports Second Quarter Financial Results for 2024 · Persbericht

6 augustus 2024 · Viatris Announces Second Quarter 2024 Dividend · Persbericht

3 juli 2024 · Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture · Persbericht

2 juli 2024 · U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation · Persbericht

25 juni 2024 · Viatris Named to TIME's World's Most Sustainable Companies 2024 List · Persbericht

7 juni 2024 · Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024 · Persbericht

4 juni 2024 · Viatris to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

3 juni 2024 · Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors · Persbericht

31 mei 2024 · Viatris to Participate in the Jeffries Global Healthcare Conference · Persbericht

21 mei 2024 · Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at Scale · Persbericht

9 mei 2024 · Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges · Persbericht

2 mei 2024 · Viatris to Participate in the BofA Securities 2024 Health Care Conference · Persbericht

1 mei 2024 · Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health · Persbericht

16 april 2024 · Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 · Persbericht

15 april 2024 · Viatris Appoints Corinne Le Goff as Chief Commercial Officer · Persbericht

1 april 2024 · Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States · Persbericht

Mijn selecties